Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

PURPOSE: Patritumab (U3-1287) is a human epidermal growth factor receptor-3 (HER3)-targeted antibody that blocks ligand-associated activation of HER3. This open-label, phase 1 and dose-finding study (ClinicalTrials.jp Identifier: JapicCTI-101262) aimed to assess the safety, pharmacokinetics, inciden...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakui, Hiroshi, Yamamoto, Noboru, Nakamichi, Shinji, Tamura, Yousuke, Nokihara, Hiroshi, Yamada, Yasuhide, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931937/
https://www.ncbi.nlm.nih.gov/pubmed/24442032
http://dx.doi.org/10.1007/s00280-014-2375-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931937/
https://www.ncbi.nlm.nih.gov/pubmed/24442032
http://dx.doi.org/10.1007/s00280-014-2375-2

Ejemplares similares